FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911588836> ?p ?o ?g. }

• W2911588836 endingPage "1348" @default.
• W2911588836 startingPage "1336" @default.
• W2911588836 abstract "Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as a treatment to raise platelet counts (PCs) in patients with thrombocytopenia and CLD undergoing invasive procedures. L‐PLUS 2 was a global, phase 3, randomized, double‐blind, placebo‐controlled study. Adults with CLD and baseline PCs < 50 × 10 9 /L were randomized to receive once‐daily lusutrombopag 3 mg or placebo ≤ 7 days before an invasive procedure scheduled 2‐7 days after the last dose. The primary endpoint was avoidance of preprocedure platelet transfusion and avoidance of rescue therapy for bleeding. A key secondary endpoint was number of days PCs were ≥ 50 × 10 9 /L throughout the study. Safety analysis was performed on patients who received at least one dose of study drug. This study occurred between June 15, 2015, and April 19, 2017, with a total of 215 randomized patients (lusutrombopag, 108; placebo, 107); 64.8% (70/108) of patients in the lusutrombopag group versus 29.0% (31/107) in the placebo group met the primary endpoint ( P < 0.0001; difference of proportion 95% confidence interval [CI], 36.7 [24.9, 48.5]). The median duration of PCs ≥ 50 × 10 9 /L was 19.2 days with lusutrombopag (without platelet transfusion) compared with 0.0 in the placebo group (with platelet transfusion) ( P = 0.0001). Most adverse events were mild or moderate in severity, and rates were similar in the lusutrombopag and placebo groups (47.7% and 48.6%, respectively). Conclusion: Lusutrombopag was superior to placebo for reducing the need for platelet transfusions and achieved durable PC response in patients with thrombocytopenia and CLD undergoing invasive procedures, with a safety profile similar to placebo." @default.
• W2911588836 created "2019-02-21" @default.
• W2911588836 creator A5000898451 @default.
• W2911588836 creator A5000989908 @default.
• W2911588836 creator A5003885788 @default.
• W2911588836 creator A5006635391 @default.
• W2911588836 creator A5011641267 @default.
• W2911588836 creator A5026430959 @default.
• W2911588836 creator A5039696464 @default.
• W2911588836 creator A5053291346 @default.
• W2911588836 creator A5061825110 @default.
• W2911588836 creator A5062023983 @default.
• W2911588836 creator A5062593266 @default.
• W2911588836 creator A5063435962 @default.
• W2911588836 creator A5066843665 @default.
• W2911588836 creator A5067249056 @default.
• W2911588836 creator A5072500126 @default.
• W2911588836 creator A5073880705 @default.
• W2911588836 creator A5077636145 @default.
• W2911588836 creator A5081943980 @default.
• W2911588836 creator A5088845309 @default.
• W2911588836 date "2019-03-15" @default.
• W2911588836 modified "2023-10-17" @default.
• W2911588836 title "Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)" @default.
• W2911588836 cites W1973631133 @default.
• W2911588836 cites W1999151899 @default.
• W2911588836 cites W2009582444 @default.
• W2911588836 cites W2014780671 @default.
• W2911588836 cites W2017955228 @default.
• W2911588836 cites W2032809132 @default.
• W2911588836 cites W2038346589 @default.
• W2911588836 cites W2086252784 @default.
• W2911588836 cites W2096230132 @default.
• W2911588836 cites W2108532099 @default.
• W2911588836 cites W2117740735 @default.
• W2911588836 cites W2131110767 @default.
• W2911588836 cites W2154487736 @default.
• W2911588836 cites W2167147321 @default.
• W2911588836 cites W2199242724 @default.
• W2911588836 cites W2396586509 @default.
• W2911588836 cites W2529128457 @default.
• W2911588836 cites W2553731919 @default.
• W2911588836 cites W2567429012 @default.
• W2911588836 cites W2591834295 @default.
• W2911588836 cites W2778465031 @default.
• W2911588836 cites W2804718317 @default.
• W2911588836 cites W2808243020 @default.
• W2911588836 cites W2808847779 @default.
• W2911588836 cites W2883884766 @default.
• W2911588836 cites W2886985238 @default.
• W2911588836 cites W2887140939 @default.
• W2911588836 cites W2903290230 @default.
• W2911588836 doi "https://doi.org/10.1002/hep.30561" @default.
• W2911588836 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6849531" @default.
• W2911588836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30762895" @default.
• W2911588836 hasPublicationYear "2019" @default.
• W2911588836 type Work @default.
• W2911588836 sameAs 2911588836 @default.
• W2911588836 citedByCount "105" @default.
• W2911588836 countsByYear W29115888362019 @default.
• W2911588836 countsByYear W29115888362020 @default.
• W2911588836 countsByYear W29115888362021 @default.
• W2911588836 countsByYear W29115888362022 @default.
• W2911588836 countsByYear W29115888362023 @default.
• W2911588836 crossrefType "journal-article" @default.
• W2911588836 hasAuthorship W2911588836A5000898451 @default.
• W2911588836 hasAuthorship W2911588836A5000989908 @default.
• W2911588836 hasAuthorship W2911588836A5003885788 @default.
• W2911588836 hasAuthorship W2911588836A5006635391 @default.
• W2911588836 hasAuthorship W2911588836A5011641267 @default.
• W2911588836 hasAuthorship W2911588836A5026430959 @default.
• W2911588836 hasAuthorship W2911588836A5039696464 @default.
• W2911588836 hasAuthorship W2911588836A5053291346 @default.
• W2911588836 hasAuthorship W2911588836A5061825110 @default.
• W2911588836 hasAuthorship W2911588836A5062023983 @default.
• W2911588836 hasAuthorship W2911588836A5062593266 @default.
• W2911588836 hasAuthorship W2911588836A5063435962 @default.
• W2911588836 hasAuthorship W2911588836A5066843665 @default.
• W2911588836 hasAuthorship W2911588836A5067249056 @default.
• W2911588836 hasAuthorship W2911588836A5072500126 @default.
• W2911588836 hasAuthorship W2911588836A5073880705 @default.
• W2911588836 hasAuthorship W2911588836A5077636145 @default.
• W2911588836 hasAuthorship W2911588836A5081943980 @default.
• W2911588836 hasAuthorship W2911588836A5088845309 @default.
• W2911588836 hasBestOaLocation W29115888361 @default.
• W2911588836 hasConcept C126322002 @default.
• W2911588836 hasConcept C141071460 @default.
• W2911588836 hasConcept C142724271 @default.
• W2911588836 hasConcept C168563851 @default.
• W2911588836 hasConcept C197934379 @default.
• W2911588836 hasConcept C203092338 @default.
• W2911588836 hasConcept C204787440 @default.
• W2911588836 hasConcept C27081682 @default.
• W2911588836 hasConcept C2776689292 @default.
• W2911588836 hasConcept C2777214474 @default.
• W2911588836 hasConcept C2779102576 @default.
• W2911588836 hasConcept C44249647 @default.
• W2911588836 hasConcept C71924100 @default.

• next